Vireo Growth (VREOF) Revenue Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -0.81% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.24% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.92% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 4.88% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 39.49% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 10.23% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 335.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 333.47% |
| Dec 31, 2025 | 317.65% |
| Sep 30, 2025 | 264.21% |
| Jun 30, 2025 | 91.42% |
| Mar 31, 2025 | 1.71% |
| Dec 31, 2024 | 3.52% |
| Sep 30, 2024 | 1.99% |
| Jun 30, 2024 | 24.32% |
| Mar 31, 2024 | 26.19% |
| Dec 31, 2023 | 26.94% |
| Sep 30, 2023 | 30.87% |
| Jun 30, 2023 | -4.24% |
| Mar 31, 2023 | 22.06% |
| Dec 31, 2022 | 39.45% |
| Sep 30, 2022 | 41.02% |
| Jun 30, 2022 | 48.20% |
| Mar 31, 2022 | 18.56% |
| Dec 31, 2021 | 10.11% |
| Sep 30, 2021 | 7.16% |
| Jun 30, 2021 | 16.50% |